HRTX - Biotech Shares Up Sharply Following Quarterly Results

2023-11-15 12:35:40 ET

A California-based %Biotech company is stealing the show so far during Wednesday’s session following yesterday’s earnings beat. According to some analysts, the company beat EPS by $0.14.

Shares of %HeronTherapeutics (Nasdaq: HRTX) rallied strongly up to $0.895/share (+65.74%) at the early session high after traders were able to digest the financial information. This move goes hand in hand with the massive uplift the biotech sector has gotten over the last few months.

Heron Therapeutics Inc () is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.